ZACHARY HELMICK: Open Payments
NPI 1245838341 · GALVESTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,757 in 91 payments from 19 companies in 2025. Trend: 2023 $1,589 · 2024 $1,546 · 2025 $1,757
Food & beverage: $1,757
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 17 | $245 |
| AstraZeneca Pharmaceuticals LP | 2 | $146 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $138 |
| ABBVIE INC. | 9 | $138 |
| Otsuka America Pharmaceutical, Inc. | 7 | $122 |
| Novo Nordisk Inc | 7 | $121 |
| Astellas Pharma US Inc | 5 | $108 |
| Amgen Inc. | 6 | $102 |
| PFIZER INC. | 4 | $84 |
| Janssen Pharmaceuticals, Inc | 4 | $78 |
Products named: REXULTI, TRELEGY ELLIPTA, AIRSUPRA, JARDIANCE, Veozah, VRAYLAR, SPRAVATO, TZIELD.
Industry payments across TX — which companies pay providers there.
